IS4910A - Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata - Google Patents

Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata

Info

Publication number
IS4910A
IS4910A IS4910A IS4910A IS4910A IS 4910 A IS4910 A IS 4910A IS 4910 A IS4910 A IS 4910A IS 4910 A IS4910 A IS 4910A IS 4910 A IS4910 A IS 4910A
Authority
IS
Iceland
Prior art keywords
pde
phosphodiesterase
type
necrosis factor
tumor necrosis
Prior art date
Application number
IS4910A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4910A publication Critical patent/IS4910A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS4910A 1996-06-25 1998-11-27 Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata IS4910A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25
PCT/IB1997/000630 WO1997049702A1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Publications (1)

Publication Number Publication Date
IS4910A true IS4910A (is) 1998-11-27

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4910A IS4910A (is) 1996-06-25 1998-11-27 Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata

Country Status (42)

Country Link
US (1) US6040329A (is)
EP (1) EP0912558B1 (is)
JP (1) JP3152940B2 (is)
KR (1) KR20000022516A (is)
CN (1) CN1080260C (is)
AP (1) AP1025A (is)
AR (1) AR007456A1 (is)
AT (1) ATE244713T1 (is)
AU (1) AU716376B2 (is)
BG (1) BG64052B1 (is)
BR (1) BR9712782A (is)
CA (1) CA2258285C (is)
CO (1) CO4900056A1 (is)
CZ (1) CZ423398A3 (is)
DE (1) DE69723447T2 (is)
DK (1) DK0912558T3 (is)
DZ (1) DZ2254A1 (is)
EA (1) EA002274B1 (is)
ES (1) ES2201299T3 (is)
GT (1) GT199700075A (is)
HN (1) HN1997000079A (is)
HR (1) HRP970350B1 (is)
HU (1) HUP9903009A3 (is)
ID (1) ID18579A (is)
IL (1) IL127036A (is)
IS (1) IS4910A (is)
MA (1) MA24225A1 (is)
MY (1) MY116915A (is)
NO (1) NO986103D0 (is)
NZ (1) NZ332752A (is)
OA (1) OA10934A (is)
PA (1) PA8432301A1 (is)
PL (1) PL330974A1 (is)
PT (1) PT912558E (is)
SI (1) SI0912558T1 (is)
SK (1) SK176598A3 (is)
TN (1) TNSN97108A1 (is)
TR (1) TR199802685T2 (is)
TW (1) TW434237B (is)
WO (1) WO1997049702A1 (is)
YU (1) YU60198A (is)
ZA (1) ZA975581B (is)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CA2264798A1 (en) * 1996-09-04 1998-03-12 Pfizer Inc. Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
US6391872B1 (en) * 1997-11-04 2002-05-21 Pfizer Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
US6716978B2 (en) * 1997-11-04 2004-04-06 Pfizer Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
AU2002255263B2 (en) * 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
DK1908463T3 (da) 2001-12-14 2011-11-28 Merck Serono Sa Fremgangsmåder til at inducere ægløsning ved anvendelse af en ikke polypeptid-CAMP-niveaumodulator
HRP20050082A2 (en) * 2002-07-19 2005-06-30 Memory Pharmaceuticals Corporation 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
AU2003256616B2 (en) 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
RU2356893C2 (ru) * 2002-11-19 2009-05-27 Мемори Фармасьютиклз Корпорейшн Ингибиторы фосфодиэстеразы 4
BRPI0409888A (pt) * 2003-04-18 2006-05-23 Memory Pharm Corp derivados de pirazol como inibidores de fosfodiesterase 4, composto, composição farmacêutica, método para efetuar a inibição da enzima pde4, incrementar a cognição e/ou tratar a psicose em um paciente, método para o tratamento de um paciente que tem uma doença que envolve nìveis de camp diminuìdos, método para o tratamento de um paciente que sofre de uma doença alérgica ou inflamatória e método para o tratamento de um paciente que sofre de neurodegeneração resultante de uma doença ou de um ferimento
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2008516964A (ja) * 2004-10-15 2008-05-22 メモリー ファーマシューティカルス コーポレーション ホスホジエステラーゼ４阻害剤としてのピラゾール誘導体
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
SI2124944T1 (sl) 2007-03-14 2012-05-31 Ranbaxy Lab Ltd Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP5641664B2 (ja) * 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (is) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
CA2133439C (en) * 1992-04-02 2005-07-26 Siegfried Benjamin Christensen, Iv Compounds useful for treating allergic and inflammatory diseases
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
PL319758A1 (en) * 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines

Also Published As

Publication number Publication date
CO4900056A1 (es) 2000-03-27
SK176598A3 (en) 2000-06-12
DE69723447T2 (de) 2003-12-24
KR20000022516A (ko) 2000-04-25
AU716376B2 (en) 2000-02-24
CN1223651A (zh) 1999-07-21
PT912558E (pt) 2003-11-28
MA24225A1 (fr) 1997-12-31
EP0912558A1 (en) 1999-05-06
CZ423398A3 (cs) 1999-12-15
TW434237B (en) 2001-05-16
NZ332752A (en) 2001-04-27
BG64052B1 (bg) 2003-11-28
EA199801047A1 (ru) 1999-06-24
BR9712782A (pt) 1999-12-07
BG103056A (en) 1999-10-29
TNSN97108A1 (fr) 2005-03-15
WO1997049702A1 (en) 1997-12-31
YU60198A (sh) 1999-09-27
JPH11514668A (ja) 1999-12-14
HUP9903009A2 (hu) 2000-05-28
IL127036A0 (en) 1999-09-22
DZ2254A1 (fr) 2002-12-18
OA10934A (en) 2002-02-18
CA2258285A1 (en) 1997-12-31
DE69723447D1 (de) 2003-08-14
SI0912558T1 (en) 2003-10-31
GT199700075A (es) 1998-12-04
MY116915A (en) 2004-04-30
AU2785797A (en) 1998-01-14
ID18579A (id) 1998-04-23
HRP970350B1 (en) 2003-04-30
ATE244713T1 (de) 2003-07-15
HK1018700A1 (en) 1999-12-30
IL127036A (en) 2001-06-14
AP1025A (en) 2001-11-19
ZA975581B (en) 1998-12-24
CN1080260C (zh) 2002-03-06
HRP970350A2 (en) 1998-06-30
DK0912558T3 (da) 2003-08-18
AR007456A1 (es) 1999-10-27
EA002274B1 (ru) 2002-02-28
NO986103L (no) 1998-12-23
AP9701020A0 (en) 1997-07-31
TR199802685T2 (xx) 1999-03-22
PL330974A1 (en) 1999-06-21
HUP9903009A3 (en) 2002-01-28
CA2258285C (en) 2002-11-26
PA8432301A1 (es) 1999-12-27
HN1997000079A (es) 1997-12-26
EP0912558B1 (en) 2003-07-09
ES2201299T3 (es) 2004-03-16
NO986103D0 (no) 1998-12-23
JP3152940B2 (ja) 2001-04-03
US6040329A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
IS4910A (is) Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata
IS4871A (is) Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)
IS4979A (is) Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)
FI950859A7 (fi) Arylideeni- ja heteroarylideeni-oksindolijohdannaiset tyrosiinikinaasi-inhibiittoreina
AU2002226911A1 (en) Indol derivative and their use as inhibitors of p38 kinase
SI1475377T1 (sl) Indolni derivati in njihova uporaba kot inhibitorji fosfodiesteraze 4
DK1000039T3 (da) Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
FI981437L (fi) PDE III, PDE IV ja TNF inhibiittoreina käyttökelpoisia imidejä
AP2002002392A0 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases and methods for their use
AU2002227985A1 (en) Pyrrolo (2.1-a) dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors
IL123124A0 (en) Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
NO20015062L (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
FI955661L (fi) Substituoidut beta-aryyli- ja beta-heteroaryyli-alfa-syanoakryyliamidijohdannaiset tyrosiinikinaasi-inhibiittoreina
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
GB0102712D0 (en) Cytokine Producion and Tyrosine Kinase Inhibitors